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1. Introduction
It is well documented that symptoms of hyperthyroidism may
be similar to those observed in patients with psychiatric disease,
most commonly affective disorders. Classical manifestations
reported include dysphoria, anxiety, emotional lability, tremor,
restlessness and rapid speech. Overactivity of the adrenergic
system caused by hyperthyroidism might explain the similarity to
clinical manifestations of mania and anxiety [1].
However, hyperthyroidism can also present with symptoms
more frequently described in hypothyroid states, namely sugges-
tive of depression - apathy, lethargy, fatigue, anorexia and
decreased cognition. Such an atypical presentation is especially
frequent in older people, and was ﬁrst described as apathetic
thyrotoxicosis by Lahey in 1931 [2]. The pathogenesis of
depression in hyperthyroid states in less clear: prolonged
hyperthyroidism might exhaust noradrenergic transmission and
therefore contribute to depression [1].
2. Clinical case
We report the case of MB, a 67-year-old woman whose
psychiatric admission to our Day Care Hospital was due to a
depressive episode unresponsive to antidepressant treatment. At
admission, depressive mood, anhedonia and anergia were
remarkable. Biological rhythms were unaltered. Intravenous
clomipramine was initiated (maximum dose of 225 mg id), but
after two weeks no improvement was apparent.
Further assessment brought to attention that the patient had
been medicated with levothyroxine (0.150 mg id) 7 years before,
when she was diagnosed with Hashimoto thyroiditis. Thyroid
hormone levels had been obtained six months before, and were
normal at that time. Thyroid laboratory exams performed during
admission at the Day Care Hospital documented subclinical
hyperthyroidism: supressed serum TSH (0.005uIU/mL) with
normal thyroxine (fT4) and triiodothyronine (fT3), in apparent
relation with excessive thyroid hormone therapy. A laboratorial
evaluation of thyroid autoimmunity documented moderately
elevated levels of anti-thyroperoxidase (61 IU/mL) and anti-
thyroglobulin (84 IU/mL) antibodies.
After withdrawal of hormone therapy there was dramatic
clinical improvement in a few days, with rapid remission of
depressive symptoms. Levothyroxine was reintroduced a week
later at a lower dosage (0.025 mg id), with subsequent normaliza-
tion of the thyroid laboratory parameters. Antidepressant medi-
cation was maintained in low dosage (clomipramine 75 mg id),
with sustained remission of the mood disorder during a 3-year
period of follow-up.
3. Discussion
Mood disorders attributed to the effect of medications rely on
clinical judgment about causality. Such causal relationships are
characterized by a temporal relationship between drug adminis-
tration and the onset of the mood episode, positive cases of de-
challenge and re-challenge with the substance, and plausibility for
a biological role.
In our clinical case, the withdrawal of levothyroxine and
subsequent normalization of TSH levels were quickly followed by
clinical improvement of the depressive symptoms. Besides, a
putative role for thyroid hormones in mood regulation has been
consistently demonstrated.
The patient’s history of autoimmune thyroiditis should also be
equated in what concerns her affective disorder. Autoimmune
thyroid conditions have been associated with more signiﬁcant
brain perfusion abnormalities and more severe anxiety and
depressive symptoms in euthyroid patients [1,3]. Increased
antibody reactivity to brain tissue and gangliosides has also been
reported in patients with Hashimoto’s thyroiditis [4].
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This example of depression in late life, attributed to an
underrecognized yet well-characterized presentation of hyperthy-
roidism in older people, underlines the importance of monitoring
chronic thyroid replacement therapy. In fact, subclinical hyper-
thyroidism, deﬁned as a decrease in serum TSH concentration
below the reference range, with normal serum T4 and T3
concentrations, is commonly of iatrogenic nature. Inadvert
overtreatment may in fact occur in 20% of patients medicated
with levothyroxine [5].
It should be noted that subclinical hyperthyroidism has
signiﬁcant consequences in terms of morbidity and mortality,
namely due to increased risk of atrial ﬁbrillation and osteoporosis
[6,7]. Prompt recognition and treatment is therefore mandatory.
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